-
Taxonomy & unit
-
us-gaap: USD/shares
-
Description
-
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
-
Summary
-
RVL Pharmaceuticals plc quarterly/annual Earnings Per Share, Diluted history and growth rate from Q2 2020 to Q2 2023.
- RVL Pharmaceuticals plc Earnings Per Share, Diluted for the quarter ending June 30, 2023 was -0.24 USD/shares, a 71.4% decline year-over-year.
- RVL Pharmaceuticals plc Earnings Per Share, Diluted for the twelve months ending June 30, 2023 was -0.72 USD/shares, a 4% increase year-over-year.
- RVL Pharmaceuticals plc annual Earnings Per Share, Diluted for 2022 was -0.58 USD/shares, a 39.6% increase from 2021.
- RVL Pharmaceuticals plc annual Earnings Per Share, Diluted for 2021 was -0.96 USD/shares, a 26.7% increase from 2020.
Earnings Per Share, Diluted, Trailing 12 Months (USD/shares)
Earnings Per Share, Diluted, Quarterly (USD/shares)
Earnings Per Share, Diluted, YoY Quarterly Growth (%)